In order to better explore the toxicity and the activity of high dose epirubicin (120 mg/m2, 3 weeks) we analyzed a population of 127 metastatic breast cancer patients, treated in a randomized clinical trial conducted to evaluate the cardioprotective effect of dexrazoxane against epirubicin induced cardiotoxicity. All the patients had a diagnosis of metastatic breast cancer, an ECOG performance status < or = 2 and normal hematologic, renal, hepatic and cardiac function. No prior adjuvant chemotherapy including anthracycline was allowed. Epirubicin was given at the dose of 120 mg/m2 i.v. bolus every 3 weeks. One hundred twenty five patients were evaluable for toxicity and response. Seventeen patients (11%) had a complete response and 47 patients (37%) a partial response, for an overall response rate of 48%. The median progression free and overall survivals were 8.3 months and 18.3 months, respectively. Grade 3 and 4 leukopenia were observed in 8% and 7% of the patients, respectively. The most frequent nonhematological grade 3 toxicities were alopecia (87%), nausea and vomiting (16%), and mucositis (8%). Cardiotoxicity, defined as occurrence of congestive heart failure, decrease in resting left ventricular ejection fraction (L-VEF) to < or = 45%, or 20 EF units decrease from baseline L-VEF, was observed in 19% of the patients, after a median cumulative dose of epirubicin of 720 mg/m2 (range 120-1440). This study confirms in a large series of patients the activity of high dose epirubicin; however, the high incidence of cardiotoxicity requires a careful evaluation of cardiac risk factors before treatment.
Single Agent Epirubicin as First Line Chemotherapy for Metastatic Breast Cancer Patients / A., Michelotti; M., Venturini; C., Tibaldi; C., Bengala; L., Gallo; F., Carnino; L., DEL MASTRO; R., Lionetto; E., Montanaro; R., Rosso; Conte, Pierfranco. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - STAMPA. - 59(2000), pp. 133-139.
Data di pubblicazione: | 2000 |
Titolo: | Single Agent Epirubicin as First Line Chemotherapy for Metastatic Breast Cancer Patients. |
Autore/i: | A., Michelotti; M., Venturini; C., Tibaldi; C., Bengala; L., Gallo; F., Carnino; L., DEL MASTRO; R., Lionetto; E., Montanaro; R., Rosso; Conte, Pierfranco |
Autore/i UNIMORE: | |
Rivista: | |
Volume: | 59 |
Pagina iniziale: | 133 |
Pagina finale: | 139 |
Codice identificativo ISI: | WOS:000085975000004 |
Codice identificativo Scopus: | 2-s2.0-0034008111 |
Codice identificativo Pubmed: | 10817348 |
Citazione: | Single Agent Epirubicin as First Line Chemotherapy for Metastatic Breast Cancer Patients / A., Michelotti; M., Venturini; C., Tibaldi; C., Bengala; L., Gallo; F., Carnino; L., DEL MASTRO; R., Lionetto; E., Montanaro; R., Rosso; Conte, Pierfranco. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - STAMPA. - 59(2000), pp. 133-139. |
Tipologia | Articolo su rivista |
File in questo prodotto:

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris